CelluTarget · Multifocal Motor Neuropathy · Treatments
✓ Standard of Care

Belimumab (Benlysta)

GlaxoSmithKline ↗
1
Evidence entries
0
Clinical trials
1
High-confidence findings
Overview
Treatment Details
Mechanism of Action
A monoclonal antibody that inhibits B-lymphocyte stimulator (BLyS/BAFF), a protein that promotes the survival of autoreactive B cells. By blocking BLyS, belimumab reduces the pool of B cells capable of producing pathogenic autoantibodies. Approved by the FDA in 2011, it was the first new drug approved for SLE in over 50 years, and remains one of only two therapies specifically approved for SLE.
Dosing Notes
Available as intravenous infusion (10 mg/kg every 4 weeks after loading doses) or weekly subcutaneous self-injection.
Treatment Type
pharmaceutical
Clinical Evidence
What the Evidence Shows
Each finding below is linked to its primary source. Confidence levels reflect the quality and quantity of available evidence — not CelluTarget's endorsement of any treatment.
High: Supported by multiple robust studies or regulatory approval
Moderate: Supported by limited controlled studies or consistent case series
Low: Based on case reports, expert opinion, or early-phase data only
High ConfidenceSupported by multiple robust studies or regulatory approval
Belimumab was the first SLE-specific therapy approved by the FDA in over 50 years (2011), establishing BAFF/BLyS inhibition as a validated therapeutic target with a well-established long-term safety and efficacy record.
Verified Jul 2026
Institutional Research
Systemic Lupus Erythematosus Market at a Turning Point as 6 Late-Stage Emerging Therapies Set to Redefine Treatment Landscape
Published July 2026
View source ↗
Clinical Trials
Linked Trials
No clinical trials linked to this treatment yet.
Belimumab (Benlysta) for MMN — Evidence & Clinical Trials | CelluTarget